BRIEF—Swissmedic to consider Mitsubishi Tanabe's ALS therapy for approval

Switzerland’s medicines regulator Swissmedic has accepted for review Mitsubishi Tanabe’s regulatory filing for edaravone to treat the neurological disease amyotrophic lateral sclerosis (ALS).

The therapy was approved in the firm’s native Japan in June 2015, where it is marketed as Radicut Bag, and in the USA in May 2017, where it is sold as Radicava.

As many as 500 to 600 people are estimated to be affected by ALS in Switzerland.